[ad_1]
It is about the drug Ontozry, with the active substance cenobamate. It can now be used as a complementary therapy for adults suffering from so-called focal seizures, which start in a limited part of the brain and are the most common form of epilepsy.
This means that a large proportion of the 11,000 to 13,000 epileptics in Sweden who do not respond to current epilepsy medications can be helped.
– The message is gratifying. We can now offer the most vulnerable epilepsy patients a treatment alternative that may mean that a significant proportion will be seizure-free, says Elinor Ben-Menachem, a professor of neurology at the Sahlgrenska Academy, in a news release from the Arvelle pharmaceutical company. Therapeutics, which is behind medicine.
In the study that forms the basis for EU approval, 1,900 patients received the drug, of whom eight were treated in Sweden. Of the patients who received the highest dose, 400 milligrams, 21 percent were completely seizure-free, and for 64 percent, seizures decreased by at least half. The results were published in the scientific journal The Lancet Neurology 2019.
[ad_2]
